

**Alexa Fluor® 647 anti-human CD45**

**Catalog # / Size:** 2120090 / 100 tests  
2120100 / 25 tests

2120280 / 100 µg

**Clone:** HI30

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.

**Formulation:** microg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.  
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** IV N816

**Concentration:** microg sizes: 0.2 mg/ml  
test sizes: lot-specific



Human peripheral blood lymphocytes stained with HI30 Alexa Fluor® 647

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.125 microg per million cells in 100 microL volume. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections<sup>9</sup>, inhibition of CD45 functions<sup>4</sup>, immunofluorescence<sup>11</sup>, and Western blotting<sup>3</sup>.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

- Application References:**
1. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, *et al.* 1993. *Cell* 74:143.
  3. Esser M, *et al.* 2001. *J. Virol.* 75:6173. (WB)
  4. Yamada T, *et al.* 2002. *J. Biol. Chem.* 277:28830.
  5. Nagano M, *et al.* 2007. *Blood* 110:151.
  6. Jiang Q, *et al.* 2008. *Blood* 112:2858. [PubMed](#)
  7. Morozov A, *et al.* 2010. *Clin Cancer Res.* 16:5630. [PubMed](#)
  8. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)

9. Friedman T, *et al.* 1999. *J. Immunol.* 162:5256. (IHC)
  10. Oeztuerk-Winder F, *et al.* 2012. *EMBO J.* 31:3431. (FC) [PubMed](#)
  11. Rees LE, *et al.* 2003. *Clin. Exp. Immunol.* 134:497. (IF)
  12. Lee J, *et al.* 2015. *J Exp Med.* 212:385. [PubMed](#)
  13. Breton G, *et al.* 2015. *J Exp Med.* 212:401. [PubMed](#)
  14. Marquardt N, *et al.* 2015. *J Immunol.* 6:2467. [PubMed](#)
- 

**Description:** CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

- Antigen** 1. Thomas M. 1989. *Annu. Rev. Immunol.* 7:339.
- References:** 2. Trowbridge I, *et al.* 1994. *Annu. Rev. Immunol.* 12:85.